Scarica l'app Stockscreener
0.89
0.46%
-0.0041
Dopo l'orario di chiusura:
.92
0.03
+3.37%
Precedente Chiudi:
$0.8941
Aprire:
$0.91
Volume 24 ore:
27,387
Relative Volume:
0.38
Capitalizzazione di mercato:
$28.93M
Reddito:
-
Utile/perdita netta:
$-563.30K
Rapporto P/E:
-4.4589
EPS:
-0.1996
Flusso di cassa netto:
$-22.23M
1 W Prestazione:
-4.02%
1M Prestazione:
-1.17%
6M Prestazione:
-35.06%
1 anno Prestazione:
-56.69%
Intervallo 1D:
$0.8801
$0.9399
Intervallo di 1 settimana:
$0.88
$1.02
Portata 52W:
$0.87
$2.61
Promis Neurosciences Inc Stock (PMN) Company Profile
Nome
Promis Neurosciences Inc
Settore
Industria
Telefono
416-847-6898
Indirizzo
SUITE 200, 1920 YONGE STREET, TORONTO
Confronta PMN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
0.89 | 28.93M | 0 | -563.30K | -22.23M | -0.1996 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Promis Neurosciences Inc Borsa (PMN) Ultime notizie
StockNews.com Initiates Coverage on Beasley Broadcast Group (NASDAQ:BBGI) - Defense World
Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference - The Manila Times
ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire
ProMIS Neurosciences Updates Corporate Presentation in Recent 8-K Filing - Defense World
Vanda Pharmaceuticals Files for New Drug Application for Tradipitant for Motion Sickness Treatment - Defense World
ProMIS Neurosciences Highlights Neurodegenerative Disease Focus - TipRanks
ProMIS Neurosciences launch Phase Ia AβO Alzheimer’s trial - MSN
ProMIS Neurosciences Issues Letter to Shareholders - Markets Insider
Crude Oil WTI (CLN25) Quote - The Globe and Mail
Crude Oil Brent (F) (QAJ23) Quote - The Globe and Mail
ProMIS Neurosciences Launches Phase 1b Trial for Alzheimer’s - TipRanks
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer's Disease - The Manila Times
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones - The Manila Times
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease - GlobeNewswire
ProMIS Neurosciences faces Nasdaq delisting over share price - Investing.com
Nonfat Dry Milk (DFZ25) Quote - The Globe and Mail
Berkshire Hathaway Cl B (BRK-B-N) QuotePress Release - The Globe and Mail
ProMIS Neurosciences (NASDAQ:PMN) Shares Up 2.8% – Should You Buy? - Defense World
ProMIS Neurosciences stock hits 52-week low at $0.88 By Investing.com - Investing.com Nigeria
ProMIS Neurosciences stock hits 52-week low at $0.88 - Investing.com
Vertiv Holdings Llc. (VRT-N) QuotePress Release - The Globe and Mail
ProMIS Neurosciences, Inc. (NASDAQ:PMN) Short Interest Down 16.6% in November - Defense World
ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference - GlobeNewswire
ProMIS Neurosciences stock hits 52-week low at $0.91 - Investing.com
ProMIS Neurosciences stock hits 52-week low at $0.91 By Investing.com - Investing.com Australia
ProMIS Neurosciences Announces Third Quarter Financial Results and Recent HighlightsOn November 14, 2024, ProMIS Neurosciences Inc. (Nasdaq: PMN) shared its financial outcomes for the third quarter ended September 30, 2024. The company provide - Defense World
ProMIS Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
GREAT POINT PARTNERS LLC Acquires Shares in ProMIS Neurosciences Inc - GuruFocus.com
ProMIS Neurosciences Inc (PMN) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires New Stake in ProMIS Neurosciences Inc - GuruFocus.com
ProMIS Neurosciences Inc Reports Q3 2024 GAAP EPS of $0.31, Surp - GuruFocus.com
ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights - GlobeNewswire
ProMIS Reports Positive Phase 1a Results for Alzheimer's Drug, Secures $30.3M Financing | PMN Stock News - StockTitan
ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference - GlobeNewswire
'Animal spirits' set to drive S&P 500 to 6,600 by mid-2025, Evercore says - Investing.com
Rising Revenue & Strategic Pipeline Advances Propel Biotech Growth Trajectory - Streetwise Reports
New Blood Cancer Treatment Shows Continued Response - Streetwise Reports
ProMIS Neurosciences (STU:23J0) PensionAndRetirementBenefit : €0.43 Mil (As of Jun. 2024) - GuruFocus.com
Biotech Shares Positive Phase I Data for Alzheimer's Treatment - Streetwise Reports
Capricor Therapeutics (CAPR) Faces 5% Drop Amid Industry Slump - GuruFocus.com
ProMIS Neurosciences Presents Positive Data from PMN310 - GlobeNewswire
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference - StockTitan
Boston Biotech Announces Novartis Collaboration - Streetwise Reports
ProMIS Neurosciences, Inc. (NASDAQ:PMN): Among The 10 Oversold Canadian Stocks to Buy Right Now - Insider Monkey
10 Oversold Canadian Stocks to Buy Right Now - Insider Monkey
ProMIS Neurosciences stock hits 52-week low at $0.92 - Investing.com India
ProMIS Neurosciences stock hits 52-week low at $0.92 By Investing.com - Investing.com South Africa
Promis Neurosciences Inc Azioni (PMN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.49%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):